Nomura Holdings Inc. Acquires Shares of 7,192 LivaNova PLC (NASDAQ:LIVN)

Nomura Holdings Inc. bought a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 7,192 shares of the company's stock, valued at approximately $333,000.

Several other hedge funds have also recently modified their holdings of LIVN. KBC Group NV boosted its holdings in shares of LivaNova by 130.5% in the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after acquiring an additional 56,580 shares during the period. Rhumbline Advisers increased its stake in LivaNova by 0.5% in the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after acquiring an additional 899 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of LivaNova by 2.6% during the 4th quarter. Principal Financial Group Inc. now owns 175,878 shares of the company's stock valued at $8,145,000 after purchasing an additional 4,476 shares during the last quarter. Paradice Investment Management LLC raised its holdings in shares of LivaNova by 15.3% during the 4th quarter. Paradice Investment Management LLC now owns 486,821 shares of the company's stock valued at $22,545,000 after buying an additional 64,680 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its position in LivaNova by 122.8% in the 4th quarter. New York State Common Retirement Fund now owns 37,557 shares of the company's stock worth $1,739,000 after buying an additional 20,699 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

LivaNova Trading Down 1.7%

Shares of NASDAQ LIVN traded down $0.75 during trading hours on Wednesday, hitting $43.27. The company's stock had a trading volume of 69,180 shares, compared to its average volume of 649,480. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $61.94. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of 103.17 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The business has a 50-day simple moving average of $38.86 and a 200-day simple moving average of $44.48.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Barclays reduced their target price on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Robert W. Baird boosted their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a research report on Tuesday, May 20th. Finally, Stifel Nicolaus decreased their price target on LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.